恩杂鲁胺Xtandi（enzalutamide）

Enzalutamide Xtandi is suitable for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel.

This product is a capsule, 120 tablets per bottle, each tablet contains 40 mg of active ingredient. The recommended dosage is once a day, 4 capsules each time (160 mg), which need to be swallowed whole.

In the side effects and warnings of Enzalutamide Xtandi, because it can affect the nervous system, patients need to be closely observed for the possibility of epileptic seizures. If there is a possibility of epileptic seizures, the administration of Enzalutamide Xtandi should be stopped immediately.

Enzalutamide Xtandi cannot be used for pregnant women. Only when the effect of the drug is far greater than pregnancy, pregnant women should be advised to cancel their pregnancy plans.